Fixed-Fee Engagements → Accelerated Project Completion

Genetic and Diagnostic Lab Valuations Rooted in Healthcare Expertise

Looking for an independent and defensible medical laboratory valuation for a transaction, litigation, or regulatory review? With over 50 years of combined valuation experience, HealthValue Group (HVG) has your need for unbiased and defensible valuation covered. 

Comprehensive Medical Laboratory Valuations

Genetic and diagnostic labs are some of the most critical healthcare facilities. Given their central function and complex revenue models, accurate valuation is essential for transactions, regulatory compliance, financial reporting, and strategic planning. 

HVG brings deep, healthcare-specific expertise to each valuation. Leaning on decades of combined industry experience, our team understands the operational and regulatory complexities unique to the sector and the key value drivers of lab businesses. 

We apply proven methodologies tailored to your specific practice, allowing us to deliver defensible medical lab appraisals that support confident, data-driven decision-making while withstanding regulatory reviews. 

Cost of Weak Genetic and Diagnostic Lab Valuation

Without a proper valuation, a medical lab is at risk in a variety of ways.

Medical Laboratory Value Drivers

Several components drive the value of a medical laboratory: 

How We Conduct Diagnostic and Genetic Lab Valuations

Why Choose HealthValue Group for Genetic and Diagnostic Lab Valuation?

Our valuation team has a combined 50 years of healthcare-specific experience. We provide clients with unbiased valuations and FMV opinions, supported by detailed documentation. They can rely on anything from buy-ins and mergers to sales, regulatory reviews, and succession planning.  

By choosing HVG, you get: 

Other Healthcare Businesses We Value

ASC valuations focus on physician alignment, procedure volume, payer mix, reimbursement rates, and operational strength.

Valuations are driven by the ability to generate consistent cash flow, patient volume, and efficient collection of receivables.  

Key drivers include payer mix, clinical quality, referral stability, HHVBP performance, and audit outcomes.

Value is driven by high-reimbursement case mix supported by strong physician alignment and utilization.

Value depends on technology scalability, adoption trends, and the ability to navigate licensure and reimbursement regulations.

Appraisals are based on patient demand, Medicare reimbursement, compliance, capital intensity, and clinical staffing.

Key factors include scale, product mix, reimbursement stability, and compliance with DMEPOS billing and accreditation standards.

Valuations are based on modality mix, reimbursement, accreditation, payer mix, referrals, and equipment utilization.

Testimonials

Quote Icon

I just wanted to say thank you for the exceptional diligence and speed in helping us with our critical FMV efforts. I honestly didn’t think it would be possible to meet our deadline and we were already prepared to postpone the meeting, but incredibly you came through, and we were able to move forward to the pleasant surprise of all parties involved…

Eddie Kalmykov, Ph.D.

AltaThera Pharmaceuticals

Quote Icon

I want to share my sincere appreciation to Chris David and the HVG team for their work in helping us enhance our FMV process. Chris is extremely knowledgeable on the topic and provided great input throughout the process. The deliverables we received were thorough and well-constructed and have set us well for immediate implementation.

VP of Compliance

Life Sciences Company

Quote Icon

Great job and money well spent in hiring you and your team!! We really appreciate the effort you put into your research. It’s apparent that the judge found your method/approach more realistic than Plaintiff’s. Based on the evidence presented, the Court finds that it is more reasonable to follow the general approach of Mr. David.

Owner

DME Company

Blog

In one week in October, the Department of Justice and the HHS Office of Inspector General introduced three initiatives that

Read More

Dependable Genetic and Diagnostic Lab Valuations

Looking for expert FMV opinions for a transaction/process involving your medical lab? We got you covered. HVG employs a team of qualified and experienced valuation experts for specialized FMV assessment, commercial reasonableness assessment, and regulatory compliance reviews to support deals and decision-making. 

FAQs

What makes genetic and diagnostic lab valuations different from other healthcare valuations?

Genetic and diagnostic lab valuations are driven by assay complexity, reimbursement dynamics, and CLIA-regulated operations. Greater weight is placed on test menu economics, compliance history, and laboratory infrastructure. 

At a minimum, three years of financial statements, detailed revenue by test type, and payer reimbursement data are required to assess earnings quality and sustainability. Buyers also expect supporting data on test volumes, billing performance, and cost structure. 

Yes. Revenue concentration in a single payer or referral source directly compresses valuation multiples due to cash flow risk. Diversified contracts and stable reimbursement profiles support higher valuations. 

Yes—laboratory valuations are routinely used for financial reporting, compliance, partnership structuring, and strategic planning. They establish a defensible view of earnings quality, risk exposure, and growth capacity. 

Most lab valuations are completed within 2–6 weeks, depending on data quality, operational complexity, and regulatory scope. Multi-state licensure, complex assay menus, or incomplete data sets extend timelines. 

Costs typically range from several thousand to tens of thousands of dollars, driven by lab size, complexity, and purpose of the valuation. Transaction support, litigation, or highly regulated environments increase scope and pricing.